SRPT
Sarepta Therapeutics, Inc. · Healthcare · Biotechnology
Momentum-inputs (vergelijkbare managers):
breedte van houders -6.2% ·
aandelenstroom +24.2% ·
netto nieuwe posities -6.7%
· formule
Geconcentreerde accumulatie: stijgende aandelen bij minder houders
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q2 2025
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | -1 | 19.39K | $353,037 | n/a | −2 |
| Q2 2026 | 109 | +2 | 83.38M | $1.50B | +13 | −12 |
| Q1 2026 | 111 | +1 | 76.41M | $1.66B | +6 | −6 |
| Q4 2025 | 110 | +2 | 75.97M | $1.63B | +3 | n/a |
| Q3 2025 | 17 | 0 | 44.07M | $848.49M | +2 | −3 |
| Q2 2025 | 15 | -1 | 40.14M | $686.46M | +1 | −2 |
| Q1 2025 | 13 | -1 | 11.03M | $703.96M | +1 | −2 |
| Q4 2024 | 14 | -1 | 10.27M | $1.25B | +2 | −3 |
| Q3 2024 | 14 | +1 | 7.65M | $955.24M | +1 | n/a |
| Q2 2024 | 13 | n/a | 7.85M | $1.24B | n/a | n/a |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passief) | 12.12M | n/a | $207.17M | 0.0% | n/c | 1 | SEC ↗ ×18 |
| 2 | The Vanguard Group ✦ (passief) | 9.16M | n/a | $156.64M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 3 | State Street Global Advisors ✦ (passief) | 4.70M | +15.4% | $80.28M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 4 | D. E. Shaw & Co. ✦ | 4.48M | +101548.6% | $76.58M | 0.1% | ▲ Add | 5 | SEC ↗ ×2 |
| 5 | Wellington Management ✦ | 2.53M | -4.4% | $43.27M | 0.0% | ▼ Trim | 5 | SEC ↗ ×5 |
| 6 | Two Sigma Investments ✦ | 2.16M | +292.4% | $36.97M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 7 | Geode Capital Management ✦ (passief) | 1.88M | +3.0% | $32.08M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 8 | Millennium Management ✦ | 1.06M | +413.3% | $18.16M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 9 | Norges Bank ✦ (passief) | 913.41K | -23.4% | $15.62M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 10 | Renaissance Technologies ✦ | 624.48K | Nieuw | $10.68M | 0.0% | New | 1 | SEC ↗ |
| 11 | Citadel Advisors ✦ | 302.16K | +28.1% | $5.17M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 125.98K | +2239.4% | $2.15M | 0.0% | ▲ Add | 3 | SEC ↗ ×3 |
| 13 | T. Rowe Price ✦ | 76.78K | -67.8% | $1.31M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 14 | Fisher Asset Management ✦ | 12.91K | +1.2% | $220,761 | 0.0% | ▲ Add | 5 | SEC ↗ |
| 15 | Fidelity (FMR) ✦ | 8.20K | n/a | $140,137 | 0.0% | n/c | 1 | SEC ↗ ×2 |
"Hun weging" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die manager: de overtuigingsmaatstaf. ✦ = gecureerde manager.
Nieuwe kopers
| Renaissance Technologies | $10.68M | 0.0% |
Verlaten
| Marshall Wace | $1.74M | was 0.0% |
| Bridgewater Associates | $1.26M | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 339 houders, 102.41M aandelen, $2.16B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect het vaakst nog meer bezitten: aantallen gedeeld eigendom, geen fundamentele relaties.